about
Race, healthcare access and physician trust among prostate cancer patients5-α reductase inhibitors and prostate cancer prevention: where do we turn now?The association between statin medication and progression after surgery for localized renal cell carcinoma.Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy.Perceived family history risk and symptomatic diagnosis of prostate cancer: the North Carolina Prostate Cancer Outcomes study.Review of recent evidence in support of a role for statins in the prevention of prostate cancer.Rationale for statins in the chemoprevention of prostate cancer.5-ARI use in active surveillance: Different paradigm than primary prevention but caution still needed.Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy.Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database.Knowledge and use of finasteride for the prevention of prostate cancer.Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience.Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host.The influence of statin medications on prostate-specific antigen levels.Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohort.Metformin for castrate-resistant prostate cancer: learning more about an old dog's new tricks.Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.The impact of introducing laparoscopic radical prostatectomy on surgical wait times for prostate cancer.Dissecting the Evolving Risk of Relapse over Time in Surveillance for Testicular Cancer.Postprostatectomy target-normal structure overlap volume differences using computed tomography and radioimmunoscintigraphy images for radiotherapy treatment planning.Chemoprevention of prostate cancerSeminal Plasma Lipocalin-Type Prostaglandin D Synthase: A Potential New Marker for the Diagnosis of Obstructive AzoospermiaSmall Transrectal Ultrasound Volume Predicts Clinically Significant Gleason Score Upgrading After Radical Prostatectomy: Results From the SEARCH DatabaseObesity Is Associated with Increased Prostate Growth and Attenuated Prostate Volume Reduction by DutasterideAn efficient solution to the retained Foley catheterSparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancerStatins and cancer risk: what do we know and where do we go from here?Combining prostate cancer clinical features more accurately predicts final pathologic stage than any single variable aloneThe effect of BRCA gene testing on family relationships: A thematic analysis of qualitative interviews5α-reductase inhibitors: preventing the treatableEditorial comment
P50
Q33610509-732C6F79-BE98-4ECB-A181-0728093C495FQ34020127-3030BB0A-7F10-470F-B516-086C7F13135EQ34206127-E2C4A8CC-8408-4DA8-9F68-995D3BCA8608Q34716253-931429C2-96FE-425A-9ADD-B815966D14E3Q36953757-3B802788-9EAB-4702-8B31-BF8306DE38B3Q36977609-D12B8D94-EAD8-43A5-9A4D-9F6573F4A096Q37125873-76DA3852-B385-4A36-A201-9B28753B5DF8Q37258845-568A6F0D-B99C-4547-8CEE-2B82A625CF80Q42115694-51A44125-8216-48DE-96A6-E4ABEDDA4F11Q42626418-8A3EA02C-C801-4912-BF1B-27E29ECF0326Q42631882-B132EE2F-0AE1-479E-AEFD-32117AEA2E6CQ42636800-ECFECAB6-5087-447F-8E7D-BD3AF62C804BQ42941307-FB8B3988-7A74-4F35-A7BF-CCBD6A799CF8Q43544429-CDC9CCB0-591D-4203-A935-5F143F7B60F7Q43573093-121270FC-691D-48B7-8862-045E6208954BQ43879300-6FDAA762-D16C-4C70-AA53-671D0796A813Q44840521-9CBC111A-584B-453B-8FEE-EB0C6240EAA3Q44904629-F76A8C97-DBA1-4962-A124-56E9919A72EAQ46058131-01B70D5C-53D9-41DA-96FE-C8E4AC70A579Q46299288-E8DAC60D-6A32-44D7-984D-D7EF6168926CQ50692758-48569167-A3A0-4ED2-91B9-D796212FF0ABQ51072919-30410054-CA04-4F37-B5C7-45FA98186282Q51326468-27CBCDB7-9DBD-418E-AAC0-FC744242D7CAQ52013358-2DD3EE85-8D20-48BB-BF49-6B067CF9A3BEQ52718397-A73BFFE7-05AD-4958-B088-93DCAB90592EQ53550362-087A6FE7-22D6-4867-AA0C-49E56C8FA585Q57129253-3018EADD-BB74-4A14-A359-BBB58097904BQ57941502-45E6C093-BC80-411C-B55E-C171A479E228Q57989759-D5CF470F-A530-45E0-82E6-AE92D6E19819Q63966150-2ED58F3C-C165-404E-A31B-1F963BF78F74Q79369844-71C51BF4-8F36-436B-9489-5DCE3F029944Q79755797-4987E09E-A4F0-4D42-A9B4-C47C153489F4Q79777203-9D35AF10-5A8E-4D2B-A19B-2075E91A6A0BQ81557941-C2D2F316-0D90-4304-BFB5-DEE74E81BBDBQ83944001-4873031C-DACB-421E-9F3A-34D1CCDB4221Q83948568-60125CD3-60E7-477B-A7FB-F62B71346851Q94943880-8CBF6311-ADF1-4EAC-BCC7-687413F680DC
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Robert James Hamilton
@ast
Robert James Hamilton
@en
Robert James Hamilton
@es
Robert James Hamilton
@nl
Robert James Hamilton
@sl
type
label
Robert James Hamilton
@ast
Robert James Hamilton
@en
Robert James Hamilton
@es
Robert James Hamilton
@nl
Robert James Hamilton
@sl
prefLabel
Robert James Hamilton
@ast
Robert James Hamilton
@en
Robert James Hamilton
@es
Robert James Hamilton
@nl
Robert James Hamilton
@sl
P106
P21
P31
P496
0000-0002-6715-5934